RaDiCo PID Cohort (RaDiCo-ILD Cohort in English)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-21

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to describe the phenotypic features of the paediatric and adult patients with Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse (IIP/PID), at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives

NCT06036719

Interstitial Lung Diseases

RECRUITING

A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up

NCT05810493

Interstitial Lung Disease

RECRUITING

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327

Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis +1 more

RECRUITING

Families-At-risk for Interstitial Lung Disease Study

NCT03641742

Interstitial Lung Disease Idiopathic Pulmonary Fibrosis

COMPLETED

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

NCT03261037

Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The French RaDiCo-PID : Idiopathic Interstitial Pneumopathy registry is an ongoing observational prospective and retrospective cohort with longitudinal long-term follow-up includes pediatric and adult patients with Idiopathic Interstitial Lung Disease (ILD) from the reference and competence centers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse Paediatric and Adult Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

children or adults with Idiopathic Lung Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest
* Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing
* Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise
* Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol
* Patients affiliated to the "Regime National d'Assurance Maladie"

Exclusion Criteria

* Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders
* Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol

Eligible Sex

ALL

Accepts Healthy Volunteers

No